An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- Registration Number
- NCT01339260
- Lead Sponsor
- Helsinn Healthcare SA
- Brief Summary
NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone. The objective of the study is to demonstrate that netupitant and palonosetron are more effective than palonosetron alone, to prevent nausea and vomiting induced by moderately emetogenic cancer chemotherapy after administration of repeated cycles of chemotherapy.
- Detailed Description
NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone. Study is organised in two phases: cycle-1 and a multi-cycle extension. Safety assessment is performed separately in cycle 1 (arm 1 and arm 2) and in multi-cycle extension (arm 3 and arm 4).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1455
- Naïve to cytotoxic chemotherapy. Previous biological or hormonal therapy will be permitted.
- Scheduled to receive first course of an anthracycline and cyclophosphamide containing moderately emetogenic chemotherapy (MEC) regimen for the treatment of a solid malignant tumor: cyclophosphamide I.V. (500 to 1500 mg/m2) and I.V. doxorubicin (more or equal to 40 mg/m2) or cyclophosphamide I.V. (500 to 1500 mg/m2) and I.V. epirubicin (more or equal to 60 mg/m2).
- If scheduled to receive chemotherapy agents of minimal to low emetogenic potential they could be given on any day.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
- Female patients of either non-childbearing potential or child-bearing potential with a commitment to use contraceptive methods throughout the clinical trial
- Hematologic and metabolic status adequate for receiving a moderately emetogenic regimen based on laboratory criteria (Total Neutrophils,Platelets, Bilirubin, Liver enzymes, Serum Creatinine or Creatinine Clearance)
The following inclusion criteria must be checked prior inclusion at each cycle of the Multiple-Cycle Extension:
- Participation in the study during the next cycle of chemotherapy is considered appropriate by the investigator Satisfactory study compliance in the preceding cycle of chemotherapy and related study procedures.
- Scheduled to receive the same chemotherapy regimen as cycle 1
- Adequate hematologic and metabolic status as defined for cycle 1
- If female, pregnant or lactating.
- Current use of illicit drugs or current evidence of alcohol abuse.
- Scheduled to receive any highly emetogenic chemotherapy (HEC) from Day 1 to Day 5 or moderately emetogenic chemotherapy (MEC) from Day 2 to Day 5 following the allowed MEC regimen.
- Received or is scheduled to receive radiation therapy to the abdomen or the pelvis within 1 week prior to Day 1 or between Days 1 to 5 in cycle 1.
- Any vomiting, retching, or mild nausea within 24 hours prior to Day 1.
- Symptomatic primary or metastatic central nervous system (CNS) malignancy.
- Active peptic ulcer disease, gastrointestinal obstruction, increased intracranial pressure, hypercalcemia, an active infection or any uncontrolled medical condition (other than malignancy) that, in the opinion of the investigator, may confound the results of the study, represent another potential etiology for emesis and nausea (other than chemotherapy-induced nausea and vomiting, CINV) or pose unwarranted risks in administering the study drugs to the patient.
- Known hypersensitivity or contraindication to 5-HT3 receptor antagonists or dexamethasone.
- Previously received a neurokin-1 (NK1) receptor antagonist
- Participation in a clinical trial involving oral netupitant administered in combination with palonosetron.
- Any investigational drugs taken within 4 weeks prior to Day 1 of cycle 1, and/or is scheduled to receive any investigational drug during the study.
- Systemic corticosteroid therapy at any dose within 72 hours prior to Day 1 of cycle 1.
- Scheduled to receive bone marrow transplantation and/or stem cell rescue therapy.
- Any medication with known or potential antiemetic activity within 24 hours prior to Day 1 of cycle 1
- Scheduled to receive any strong or moderate inhibitor of cytocrome P450 3A4 (CYP3A4) or its intake within 1 week prior to Day 1.
- Scheduled to receive any of the following CYP3A4 substrates: terfenadine, cisapride, astemizole, pimozide.
- Scheduled to receive any CYP3A4 inducer or its intake within 4 weeks prior to Day 1.
- History or predisposition to cardiac conduction abnormalities, except for incomplete right bundle branch block.
- History of risk factors for Torsade de Point (heart failure, hypokalemia, family history of Long QT Syndrome).
- Severe cardiovascular diseases, including myocardial infarction within 3 months prior to Day 1, unstable angina pectoris, significant valvular or pericardial disease, history of ventricular tachycardia, symptomatic Congestive Heart Failure (CHF) New York Heart Association (NYHA) class III-IV, and severe uncontrolled arterial hypertension.
- Any illness or condition that, in the opinion of the investigator, may confound the results of the study or pose unwarranted risks in administering the investigational product to the patient.
- Concurrent medical condition that would preclude administration of dexamethasone such as systemic fungal infection or uncontrolled diabetes.
The following exclusion criteria must be checked prior inclusion at each cycle of the Multiple-Cycle Extension:
- If female, pregnant or lactating
- Active infection or uncontrolled disease except for malignancy.
- Started any of the restricted medications.
- Any vomiting, retching, or mild nausea within 24 hours prior to Day 1.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Netupitant and Palonosetron+dexamethasone-cycle 1 Netupitant and Palonosetron Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule with oral dexamethasone (12 mg), both given on Day 1, prior to each scheduled chemotherapy cycle Palonosetron+dexamethasone-cycle 1 Palonosetron Oral palonosetron 0.50 mg (Aloxi) with oral dexamethasone (20 mg) both given on Day 1, prior to each scheduled chemotherapy cycle Netupitant and Palonosetron+dexamethasone-cycle 1 Dexamethasone Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule with oral dexamethasone (12 mg), both given on Day 1, prior to each scheduled chemotherapy cycle Netupitant and Palonosetron+dexamethasone-multicycle extension Netupitant and Palonosetron Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule with oral dexamethasone (12 mg), both given on Day 1, prior to each scheduled chemotherapy cycle Palonosetron+dexamethasone-cycle 1 Dexamethasone Oral palonosetron 0.50 mg (Aloxi) with oral dexamethasone (20 mg) both given on Day 1, prior to each scheduled chemotherapy cycle Netupitant and Palonosetron+dexamethasone-multicycle extension Dexamethasone Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule with oral dexamethasone (12 mg), both given on Day 1, prior to each scheduled chemotherapy cycle Palonosetron+dexamethasone-multicycle extension Palonosetron Oral palonosetron 0.50 mg (Aloxi) with oral dexamethasone (20 mg) both given on Day 1, prior to each scheduled chemotherapy cycle Palonosetron+dexamethasone-multicycle extension Dexamethasone Oral palonosetron 0.50 mg (Aloxi) with oral dexamethasone (20 mg) both given on Day 1, prior to each scheduled chemotherapy cycle
- Primary Outcome Measures
Name Time Method Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, at Cycle 1 25-120 hours
- Secondary Outcome Measures
Name Time Method Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication at Cycle 1 0-24 hours Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, at Cycle 1 0-120 hours
Trial Locations
- Locations (171)
Cancer Specialists of South Texas, P.A.
🇺🇸Corpus Christi, Texas, United States
The John R Marsh Cancer Center
🇺🇸Hagerstown, Maryland, United States
Compassionate Cancer Centre Medical Group
🇺🇸Fountain Valley, California, United States
Signal Point Clinical Research Center LLC
🇺🇸Middletown, Ohio, United States
Centro Oncologico de Integracion Regional (COIR)
🇦🇷Mendoza, Argentina
Centro Medico San Roque
🇦🇷San Miguel de Tucuman, Argentina
Mogilev Regional Oncological Dispensary [Oncology]
🇧🇾Mogilev, Belarus
IPCEM - Centro de Ciências da Saúde - Universidade de Caxias
🇧🇷Caxias do Sul, Brazil
Hospital Araújo Jorge
🇧🇷Goiânia, Brazil
Hospital Santa Cruz
🇧🇷São Paulo, Brazil
Klinika za tumore [Odjel za kemoter. i internisticku onkolog
🇭🇷Zagreb, Croatia
Bács-Kiskun Megyei Önkormányzat Kórháza, Szegedi
🇭🇺Kecskemet, Hungary
Josa Andras Oktato Korhaz [Onkologiai Osztaly]
🇭🇺Nyíregyháza, Hungary
BIBI General Hospital & Cancer Centre [Oncology]
🇮🇳Hyderabad, India
Grant Medical Foundation - Ruby Hall Clinic
🇮🇳Pune, India
Ospedale Sacro Cuore e Don Calabria - Negrar
🇮🇹Negrar, Italy
Ospedale S.Carlo di Potenza [U.O. di Oncologia Medica]
🇮🇹Potenza, Italy
Hospital de Jesus
🇲🇽Mexico, Mexico
OCA Hospital/Monterrey International Research Center
🇲🇽Monterrey, Mexico
Szpital Wojewodzki w Lomzy im. Kardynala S. Wyszynskiego
🇵🇱Lomza, Poland
Centrum Onkologii - Instytut im. Marii Sklodowskiej - Curie
🇵🇱Warszawa, Poland
Spitalul Judetean de Urgenta "Dr. Constantin Opris" Baia-Mare [Oncologie Medicala]
🇷🇴Baia-Mare, Romania
Oncolab - Oncology Center Craiova
🇷🇴Craiova, Romania
Ivanovo Regional Oncological Dispensary [Chemotherapy]
🇷🇺Ivanovo, Russian Federation
SBHI of Moscow City Oncology Clinical Hospital #62
🇷🇺Moscow, Russian Federation
GOU VPO Krasnoyarsk State Medical University n.a. prof. V.F.
🇷🇺Krasnoyarsk, Russian Federation
GUZ Regional Oncology Dispensary #2
🇷🇺Magnitogorsk, Russian Federation
Russian Cancer Research Center
🇷🇺Moscow, Russian Federation
GUZ Pyatigorsk Oncology Dispensary [Outpatient Department]
🇷🇺Pyatigorsk, Russian Federation
GUZ Perm Regional Oncology Dispensary
🇷🇺Perm, Russian Federation
FGBU Medical Radiology Scientific Center
🇷🇺Obninsk, Russian Federation
GOU VPO - Ryazan State Med. Univer. n.a. I.I.Pavlov based Ryazan Regio
🇷🇺Ryazan, Russian Federation
City Oncology Dispensary
🇷🇺Saint Petersburg, Russian Federation
FGU Research Institute of Oncology n.a. N.N.Petrov of Rosmed
🇷🇺St. Petersburg, Russian Federation
GUZ Republican Clinical Oncological Dispensary of public
🇷🇺Ufa, Russian Federation
Donetskyi oblasnyi protypukhlynnyi tsentr
🇺🇦Donetsk, Ukraine
Kharkivskyi oblasnyi onkologichnyi klinichnyi tsentr
🇺🇦Kharkiv, Ukraine
KZ KOR Kyivskyi oblasnyi onkologichnyi dyspanser
🇺🇦Kyiv, Ukraine
Odeska oblasna klinichna likarnia
🇺🇦Odessa, Ukraine
MHAT Dr. Tota Venkova [Oncology]
🇧🇬Gabrovo, Bulgaria
Apollo Gleneagles Hospitals Kolkata
🇮🇳Kolkata, India
UMHAT "Sveti Georgi" [Clinic of Oncology and Hematology]
🇧🇬Plovdiv, Bulgaria
Specialized Hospital for Active Treatment in Oncology
🇧🇬Sofia, Bulgaria
Specialized Hospital for Active Treatment of Onclogy Diseases - Sofia City
🇧🇬Sofia, Bulgaria
Pécsi Tudományegyetem Klinikai Köpont
🇭🇺Pécs, Hungary
SHATO "Sveti Mina"
🇧🇬Blagoevgrad, Bulgaria
Comprehensive Cancer Center - Vratsa Dept. of Palliative Care
🇧🇬Vratsa, Bulgaria
HCG - Multy Speciality Hospital
🇮🇳Ahmedabad, India
Centro Oncologico De Chihuahua
🇲🇽Chihuahua, Mexico
Spitalul Universitar de Urgenta Bucuresti
🇷🇴Bucuresti, Romania
Institutul Oncologic "Prof. Dr. Alex. Trestioreanu" [Sectia Clinica Radioterapie II]
🇷🇴Bucuresti, Romania
Specialized Hospital for Active Treatment of Oncology
🇧🇬Haskovo, Bulgaria
UMHAT ""Dr. Georgi Stranski"" Dept. Medical Oncology
🇧🇬Pleven, Bulgaria
UMHAT "Tsaritsa Yoanna - ISUL" Ltd.Medical Oncology Clinic
🇧🇬Sofia, Bulgaria
Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház
🇭🇺Miskolc, Hungary
B.P.Poddar Hospital and Medical Research Ltd
🇮🇳Kolkata, India
City Cancer Centre [Surgical and Medical Oncology]
🇮🇳Vijayawada, India
NZOZ Magodent - Centrum Medczyne Ostrobramska
🇵🇱Warszawa, Poland
Spitalul Clinic CF nr.2 Bucuresti [Oncologie Medicala]
🇷🇴Bucuresti, Romania
Gomel Regional Clinical Oncological Dispensary
🇧🇾Brest, Belarus
District Dispensery with Stationary - Sofia District
🇧🇬Sofia, Bulgaria
COC - Veliko Tarnovo Dept. Medical Oncology
🇧🇬Veliko Tarnovo, Bulgaria
Centro Medico Quirurgico
🇲🇽Mexico, Mexico
Institutul Regional de Oncologia
🇷🇴Iasi, Romania
Hemato-Oncology Clinic Ahmedabad Pvt Ltd
🇮🇳Ahmedabad, India
Dr. Kamahshi Memorial Hospital [Oncology]
🇮🇳Chennai, India
Yashoda B-Block Hospital
🇮🇳Hyderabad, India
Spitalul Universitar de Urgenta Elias [Oncologie Medicala]
🇷🇴Bucuresti, Romania
Wojewodzki Szpital Specjalistyczny im. M.Kopernika
🇵🇱Lodz, Poland
Charleston Hematology Oncology
🇺🇸Charleston, South Carolina, United States
Northwest Alabama Cancer Center
🇺🇸Muscle Shoals, Alabama, United States
Genesis Cancer Centre
🇺🇸Hot Springs, Arkansas, United States
Deaconess Clinic Downtown
🇺🇸Evansville, Indiana, United States
Compassionate Cancer Care Medical Group
🇺🇸Riverside, California, United States
Anniston Oncology/Regional Medical Center
🇺🇸Anniston, Alabama, United States
Compassionate Cancer Care Medical Group Inc
🇺🇸Corona, California, United States
Fallon Clinic at Worcester Medical Center
🇺🇸Worcester, Massachusetts, United States
Denver Health and Hospital Authority
🇺🇸Denver, Colorado, United States
Baptist Cancer Institute
🇺🇸Jacksonville, Florida, United States
American Institute of Research
🇺🇸Whittier, California, United States
Facey Medical Group
🇺🇸Mission Hills, California, United States
Floyd Memorial Cancer Center of Indiana
🇺🇸New Albany, Indiana, United States
Tri-County Hematology and Oncolgy Associates Inc.
🇺🇸Massillon, Ohio, United States
Instituto Ribeirãopretano de Combate ao Cancer
🇧🇷Ribeirão Preto, Brazil
Clinica de Neoplasias do Litoral
🇧🇷ItajaÃ, Brazil
Northern Utah Associates Hematology / Oncology
🇺🇸Ogden, Utah, United States
Oncotrat Oncologia Medica Ltda [Oncology]
🇧🇷Rio de Janeiro, Brazil
Hospital Italiano de Cordoba
🇦🇷Córdoba, Argentina
ISIS Clinica Especializada
🇦🇷Santa Fe, Argentina
OXION-Medicina Oncológica
🇧🇷Belo Horizonte, Brazil
Centro Oncológico Integral (COI)
🇦🇷Mar del Plata, Argentina
Hospital Moinhos de Vento
🇧🇷Porto Alegre, Brazil
Clínica Universitaria Reina Fabiola (Universidad Católica de Córdoba)
🇦🇷Córdoba, Argentina
The University of Texas Health Center
🇺🇸Tyler, Texas, United States
Instituto Oncológico de Córdoba - Sanatorio Aconcagua
🇦🇷Cordoba, Argentina
Instituto Médico CER [Oncology]
🇦🇷Quilmes, Argentina
Bobruisk Interregional Oncological Dispensary
🇧🇾Bobruisk, Belarus
Nucleo de Oncologia da Bahia
🇧🇷Salvador Bahia, Brazil
Brest Regional Oncological Dispensary
🇧🇾Brest, Belarus
Centro de Pesquisas Clínicas em Oncologia
🇧🇷Cachoeiro de Itapemirim, Brazil
State institution N.N. Alexandrov Republican Scientific and Practical Center of Oncology and Medical Radiology
🇧🇾Minsk, Belarus
Klinicki bolnicki centar Osijek [Oncology]
🇭🇷Osijek, Croatia
Minsk city Clinical Oncological Dispensary [Oncology]
🇧🇾Minsk, Belarus
Presidio Ospedaliero "Alessandro Manzoni", AO Provincia di Lecco
🇮🇹Lecco, Italy
Casa de Saude Santa Marcelina
🇧🇷São Paulo, Brazil
Opca bolnica Varazdin [Odjel za hem.onko i klin.imun.]
🇭🇷Varazdin, Croatia
Clinica De Oncologia De Porto Alegre S S Ltda
🇧🇷Porto Alegre, Brazil
Petz Aladár Megyei Oktató Kórház [Onkoradiológiai Oszt
🇭🇺Győr, Hungary
Apollo Speciality Hospital
🇮🇳Chennai, India
Shatabdhi Superspeciality Hospital
🇮🇳Nashik, India
Tumorzentrum Munchen Sued - Städtisches Klinikum [Hämato-, Onkologie + Palliativmed]
🇩🇪München, Germany
Županijska bolnica Cakovec
🇭🇷Cakovec, Croatia
KBC Rijeka [Gastroenterology]
🇭🇷Rijeka, Croatia
Opca Bolnica Zadal Ulica
🇭🇷Zadar, Croatia
Klinički bolnički centar Zagreb [Oncology]
🇭🇷Zagreb, Croatia
Opca bolnica Pula [Odjel za onklologiju]
🇭🇷Pula, Croatia
Complex Oncology Centre
🇧🇬Stara Zagora, Bulgaria
Staedtisches Krankenhaus Muenchen Neuperlach
🇩🇪München, Germany
Onkologische Gemeinschaftspraxis Dr. med M. Perker / PF Dr. med M. Sandherr
🇩🇪Weilheim, Germany
Klinik und Poliklinik für Onkologie und Hämatologie Universitatsmedizin Charite Mitte
🇩🇪Berlin, Germany
Gynäkologische Arztpraxis
🇩🇪Berlin, Germany
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz
🇭🇺Szolnok, Hungary
Sri Venkateshwara Hospital [Medical Oncology]
🇮🇳Bangalore, India
Klinicka bolnica [Sestre milosrdnice]
🇭🇷Zagreb, Croatia
OncoResearch Lerchenfeld UG
🇩🇪Hamburg, Germany
Semmelweis Egyetem Kútvölgyi Klinikai Tömb
🇭🇺Budapest, Hungary
Fővárosi Önkormányzat Uzsoki utcai Kórház
🇭🇺Budapest, Hungary
Schwerpktprxs gynäkolog Onkologie Prof. Dr. Diel, Dr. Gebert
🇩🇪Mannheim, Germany
Sujan Surgical Cancer Hospital and Amracvati Cancer Foundation
🇮🇳Amravati, India
Fondazione Poliambulanza Istituto Ospedaliero
🇮🇹Brescia, Italy
Ospedale Vito Fazzi, ASL Lecce
🇮🇹Lecce, Italy
Centro Regiomontano de Investigación Clínica
🇲🇽Monterrey, Mexico
Wojewodzki Szpital Zespolony w Elblagu, Oddzial Onkologiczny
🇵🇱Elblag, Poland
MBUZ City Clinical Hospital #1
🇷🇺Novosibirsk, Russian Federation
Niepubliczny Specjalist. Onkol. Zaklad Opieki Zdrowotnej
🇵🇱Koscierzyna, Poland
Olsztynski Osrodek Onkologiczny "KOPERNIK"
🇵🇱Olsztyn, Poland
Spitalul Clinic Judetean Mures
🇷🇴Tg Mures, Romania
Bialostockie Centrum Onkologii im. M.Sklodowskiej-Curie
🇵🇱Bialystok, Poland
Szpital Rejonowy im. dr J. Rostka w Raciborzu
🇵🇱Raciborz, Poland
Wojewodzki Szpital Specjalistyczny im. J. Korczaka
🇵🇱Slupsk, Poland
Oncomed SRL
🇷🇴Timisoara, Romania
GUZ Arkhangelsk Regional Clinical Oncological Dispensary
🇷🇺Arkhangelsk, Russian Federation
Spitalul Municipal Onesti [Sectia Oncologie Medicala]
🇷🇴Onesti, Romania
GAUZ Republic Clinical Oncology Dispensary of Ministry of Health of Republic Tatarstan
🇷🇺Kazan, Russian Federation
GUZ Lipetsk Regional Oncology Dispensary [General Oncology]
🇷🇺Lipetsk, Russian Federation
GOU VPO Saint-Petersburg State Medical University n.a. acad.
🇷🇺Saint Petersburg, Russian Federation
St. Petersburg Clinical Oncology Dispesary - 3rd Gynecology D
🇷🇺Saint Petersburg, Russian Federation
GUZ "Leningrad Regional Oncology Dispensary"
🇷🇺Saint-Petersburg, Russian Federation
GUZ Samara Regional Clinical Oncology Dispensary
🇷🇺Samara, Russian Federation
Komunalnyizaklad Miska bahatoprofilna klinichna likarnia #4
🇺🇦Dnipropetrovks, Ukraine
Stavropol Regional Clinical Oncology Dispensary
🇷🇺Stavropol, Russian Federation
GBUZ - Clinical Oncology Dispensary of MoH of Republic Bahkortostan
🇷🇺Ufa, Russian Federation
Komunalnyi "Cherkaskyi oblasnyi onkolohichnyi dyspanser" Cherkaskoi oblasnoi rady, oblasnyi onkokhimioterapevtychnyi tsentr, m. Cherkasy
🇺🇦Cherkasy, Ukraine
Rotkreuzklinikum [München]
🇩🇪München, Germany
OncoPRO GbR Dr. R. Dengler, Dr. A. Kröber Gesellschaft für klinische Studien in der ambulanten Hämatologie und Onkologie
🇩🇪Regensburg, Germany
Praxis Dr. G. Dresemann
🇩🇪Velen, Germany
Universitätsklinikum Tübingen
🇩🇪Tübingen, Germany
Wellmont Medical Associates-Oncology and Hematology
🇺🇸Bristol, Tennessee, United States
Sanatorio Parque
🇦🇷Rosario, Argentina
Kentucky Cancer Clinic
🇺🇸Hazard, Kentucky, United States
Northwest Medical Specialties
🇺🇸Tacoma, Washington, United States
Chmelnytskyi Regional Clinical Oncology Centre [Oncology]
🇺🇦Chmelnytskyi, Ukraine
Lvivskyi derzhavnyi onkologichnyi regionalnyi likuvalno diahnostychyi tsentr
🇺🇦Lviv, Ukraine
Zakarpatskyi oblasnyi klinichnyi onkodyspanser
🇺🇦Uzhgorod, Ukraine
Kyirskyi Miskyi klinichnyi onkolohichnyi tsentr
🇺🇦Kyiv, Ukraine
Poltavskyi oblasnyi klinichnyi onkolohichnyi dyspanser Pol
🇺🇦Poltava, Ukraine
Komunalnyi likuvalno-profilaktychnyi zaklad "Chernigivskyi
🇺🇦Chernigiv, Ukraine
Duke University Medical Center
🇺🇸Durham, North Carolina, United States
Piedmont Hematology Oncology Associates PA
🇺🇸Winston-Salem, North Carolina, United States
Charleston Cancer Center
🇺🇸Charleston, South Carolina, United States
Palm Beach Institute of Hematology and Oncology
🇺🇸Boynton Beach, Florida, United States